NORWICH – Norwich Pharmaceuticals has entered a new phase in its growth as a pharmaceutical manufacturer. In July of last year, they reported the acquisition of Norwich Pharmaceuticals by AFI Partners. AFI Partners has now announced the creation of a “sister” company to Norwich Pharmaceuticals, to be named “Alvogen.”

Doug Drysdale has been appointed CEO of both Alvogen and Norwich Pharmaceuticals. There is no change in local management, with Chris Calhoun remaining President of Norwich Pharmaceuticals. Alvogen will sit alongside Norwich Pharmaceuticals in the corporate structure, but will be its own legally incorporated entity.

Alvogen has the strategy of becoming a leading developer and marketer of Specialty Generic products in the US. Wherever practical, as Alvogen develops and acquires pharmaceutical products, those products will be reviewed for potential manufacture by Norwich Pharmaceuticals, bringing additional growth opportunities to both companies.

Through an investment network being utilized by AFI Partners, both Alvogen and Norwich are part of a larger international pharmaceutical organization. This international pharmaceutical group has sales in more than 30 markets, a portfolio of more than 400 branded generic products and a pipeline of almost 130 projects.